Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.91B | 29.92B | 29.85B | 29.62B | 29.99B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.91B | 29.92B | 29.85B | 29.62B | 29.99B |
| Cost of Revenue | 10.62B | 10.73B | 10.29B | 10.42B | 10.50B |
| Gross Profit | 19.29B | 19.18B | 19.56B | 19.20B | 19.49B |
| SG&A Expenses | 7.21B | 7.19B | 7.27B | 7.21B | 7.29B |
| Depreciation & Amortization | 3.10B | 3.33B | 3.57B | 3.56B | 3.61B |
| Other Operating Expenses | 469.06M | 301.04M | 151.76M | 635.12M | 227.68M |
| Total Operating Expenses | 25.88B | 25.98B | 25.92B | 26.45B | 26.34B |
| Operating Income | 4.03B | 3.94B | 3.93B | 3.17B | 3.65B |
| Income Before Tax | -818.69M | -797.11M | 1.40B | 703.04M | 1.32B |
| Income Tax Expenses | 224.59M | 96.58M | 620.97M | 442.33M | 355.19M |
| Earnings from Continuing Operations | -1.04K | -893.69 | 777.52 | 260.71 | 959.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.87M | -1.74M | -1.72M | -1.41M | -1.34M |
| Net Income | -1.05B | -895.43M | 775.80M | 259.30M | 958.61M |
| EBIT | 4.03B | 3.94B | 3.93B | 3.17B | 3.65B |
| EBITDA | 7.99B | 8.14B | 8.33B | 7.56B | 8.08B |
| EPS Basic | -0.66 | -0.56 | 0.50 | 0.17 | 0.61 |
| Normalized Basic EPS | 1.22 | 1.19 | 1.31 | 0.89 | 1.07 |
| EPS Diluted | -0.68 | -0.58 | 0.48 | 0.16 | 0.60 |
| Normalized Diluted EPS | 1.21 | 1.18 | 1.30 | 0.89 | 1.05 |
| Average Basic Shares Outstanding | 6.32B | 6.30B | 6.30B | 6.31B | 6.31B |
| Average Diluted Shares Outstanding | 6.37B | 6.35B | 6.35B | 6.33B | 6.36B |
| Dividend Per Share | 1.32 | 1.32 | 1.32 | 1.32 | 1.30 |
| Payout Ratio | -193.75% | -233.25% | 270.24% | 803.40% | 217.56% |